A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
IDEAYA Biosciences
University Hospital, Angers
A2 Biotherapeutics Inc.
Azienda Ospedaliero-Universitaria di Parma
CRISPR Therapeutics
Stella Pharma Corporation
Nurix Therapeutics, Inc.
TCR2 Therapeutics
TCR2 Therapeutics
Context Therapeutics Inc.
NuCana plc
Telix Pharmaceuticals (Innovations) Pty Limited
Medicenna Therapeutics, Inc.
Ascentage Pharma Group Inc.
Cancer Research UK
Mayo Clinic
Alliance for Clinical Trials in Oncology
BerGenBio ASA
Aminex Therapeutics, Inc.
University Hospital, Antwerp
UTC Therapeutics Inc.
Centre Hospitalier Universitaire Vaudois
Translational Research in Oncology
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Jules Bordet Institute
Institut Bergonié
Quadriga Biosciences, Inc.
ImmVira Pharma Co. Ltd
Abramson Cancer Center at Penn Medicine
National Institutes of Health Clinical Center (CC)
Fox Chase Cancer Center
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Chinese PLA General Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)